Rho-associated Coiled-coil-forming Kinases (ROCKs): Potential Targets for the Treatment of Atherosclerosis and Vascular Disease

Overview

Journal Trends Pharmacol Sci

Specialty Pharmacology

Date 2011 Jan 19

PMID 21242007

Citations 69

Authors

Qian Zhou

Christoph Gensch

James K Liao

Affiliations

Soon will be listed here.

Abstract

ROCKs are important regulators of the actin cytoskeleton. Because changes in the actin cytoskeleton underlie vascular contractility and remodeling, inflammatory cell recruitment, and cell proliferation, it is likely that the Rho/ROCK pathway will play a central role in mediating vascular function. Indeed, increased ROCK activity is observed in cerebral and coronary vasospasm, hypertension, vascular inflammation, arteriosclerosis, and atherosclerosis. Recent experimental and clinical studies suggest that inhibition of ROCK could be a promising target for the treatment of cardiovascular disease. For example, inhibition of ROCK might be the underlying mechanism by which statins or HMG-CoA reductase inhibitors exert their therapeutic benefits beyond cholesterol reduction. In this review we summarize current understanding of the crucial role of RhoA/ROCK pathway in the regulation of vascular function and discuss its therapeutic potential in the treatment of atherosclerosis and vascular disease.

Citing Articles

Novel insights into the ROCK-JAK-STAT signaling pathway in upper respiratory tract infections and neurodegenerative diseases.

Li J, Mao N, Wang Y, Deng S, Chen K Mol Ther. 2024; 33(1):32-50.

PMID: 39511889 PMC: 11764622. DOI: 10.1016/j.ymthe.2024.11.011.

Abnormal TPM2 expression is involved in regulation of atherosclerosis progression via mediating RhoA signaling .

Zhang J, Zhang C, Miao L, Meng Z, Gu N, Song G Arch Med Sci. 2024; 20(4):1197-1208.

PMID: 39439675 PMC: 11493070. DOI: 10.5114/aoms/139235.

How Protein Depletion Balances Thrombosis and Bleeding Risk in the Context of Platelet's Activatory and Negative Signaling.

Montecino-Garrido H, Trostchansky A, Espinosa-Parrilla Y, Palomo I, Fuentes E Int J Mol Sci. 2024; 25(18).

PMID: 39337488 PMC: 11432290. DOI: 10.3390/ijms251810000.

Myosin light chain phosphatase is a downstream target of Rho-kinase in endothelin-1-induced transactivation of the TGF-β receptor.

Rezaei M, Mehta J, Zadeh G, Khedri A, Rezaei H Cell Biochem Biophys. 2024; 82(2):1109-1120.

PMID: 38834831 DOI: 10.1007/s12013-024-01262-4.

Smoking cessation and vascular endothelial function.

Higashi Y Hypertens Res. 2023; 46(12):2670-2678.

PMID: 37828134 PMC: 10695829. DOI: 10.1038/s41440-023-01455-z.

References

Shirao S, Fujisawa H, Kudo A, Kurokawa T, Yoneda H, Kunitsugu I . Inhibitory effects of eicosapentaenoic acid on chronic cerebral vasospasm after subarachnoid hemorrhage: possible involvement of a sphingosylphosphorylcholine-rho-kinase pathway. Cerebrovasc Dis. 2008; 26(1):30-7. DOI: 10.1159/000135650. View

Sebbagh M, Renvoize C, Hamelin J, Riche N, Bertoglio J, Breard J . Caspase-3-mediated cleavage of ROCK I induces MLC phosphorylation and apoptotic membrane blebbing. Nat Cell Biol. 2001; 3(4):346-52. DOI: 10.1038/35070019. View

Zhou Q, Liao J . Rho kinase: an important mediator of atherosclerosis and vascular disease. Curr Pharm Des. 2009; 15(27):3108-15. PMC: 2896789. DOI: 10.2174/138161209789057986. View

Yamaguchi H, Kasa M, Amano M, Kaibuchi K, Hakoshima T . Molecular mechanism for the regulation of rho-kinase by dimerization and its inhibition by fasudil. Structure. 2006; 14(3):589-600. DOI: 10.1016/j.str.2005.11.024. View

Maekawa M, Ishizaki T, Boku S, Watanabe N, Fujita A, Iwamatsu A . Signaling from Rho to the actin cytoskeleton through protein kinases ROCK and LIM-kinase. Science. 1999; 285(5429):895-8. DOI: 10.1126/science.285.5429.895. View

Masumoto A, Mohri M, Shimokawa H, Urakami L, Usui M, Takeshita A . Suppression of coronary artery spasm by the Rho-kinase inhibitor fasudil in patients with vasospastic angina. Circulation. 2002; 105(13):1545-7. DOI: 10.1161/hc1002.105938. View

Amano M, Nakayama M, Kaibuchi K . Rho-kinase/ROCK: A key regulator of the cytoskeleton and cell polarity. Cytoskeleton (Hoboken). 2010; 67(9):545-54. PMC: 3038199. DOI: 10.1002/cm.20472. View

Hiroki J, Shimokawa H, Higashi M, Morikawa K, Kandabashi T, Kawamura N . Inflammatory stimuli upregulate Rho-kinase in human coronary vascular smooth muscle cells. J Mol Cell Cardiol. 2004; 37(2):537-46. DOI: 10.1016/j.yjmcc.2004.05.008. View

Ito K, Hirooka Y, Kishi T, Kimura Y, Kaibuchi K, Shimokawa H . Rho/Rho-kinase pathway in the brainstem contributes to hypertension caused by chronic nitric oxide synthase inhibition. Hypertension. 2004; 43(2):156-62. DOI: 10.1161/01.HYP.0000114602.82140.a4. View

10.

Wolfrum S, Dendorfer A, Rikitake Y, Stalker T, Gong Y, Scalia R . Inhibition of Rho-kinase leads to rapid activation of phosphatidylinositol 3-kinase/protein kinase Akt and cardiovascular protection. Arterioscler Thromb Vasc Biol. 2004; 24(10):1842-7. PMC: 2649731. DOI: 10.1161/01.ATV.0000142813.33538.82. View

11.

Shimokawa H, Morishige K, Miyata K, Kandabashi T, Eto Y, Ikegaki I . Long-term inhibition of Rho-kinase induces a regression of arteriosclerotic coronary lesions in a porcine model in vivo. Cardiovasc Res. 2001; 51(1):169-77. DOI: 10.1016/s0008-6363(01)00291-7. View

12.

Riento K, Ridley A . Rocks: multifunctional kinases in cell behaviour. Nat Rev Mol Cell Biol. 2003; 4(6):446-56. DOI: 10.1038/nrm1128. View

13.

Kozasa T, Jiang X, Hart M, Sternweis P, Singer W, GILMAN A . p115 RhoGEF, a GTPase activating protein for Galpha12 and Galpha13. Science. 1998; 280(5372):2109-11. DOI: 10.1126/science.280.5372.2109. View

14.

Amano M, Ito M, Kimura K, Fukata Y, Chihara K, Nakano T . Phosphorylation and activation of myosin by Rho-associated kinase (Rho-kinase). J Biol Chem. 1996; 271(34):20246-9. DOI: 10.1074/jbc.271.34.20246. View

15.

Suzuki Y, Shibuya M, Satoh S, Sugiyama H, Seto M, Takakura K . Safety and efficacy of fasudil monotherapy and fasudil-ozagrel combination therapy in patients with subarachnoid hemorrhage: sub-analysis of the post-marketing surveillance study. Neurol Med Chir (Tokyo). 2008; 48(6):241-7. DOI: 10.2176/nmc.48.241. View

16.

Coleman M, Sahai E, Yeo M, Bosch M, Dewar A, Olson M . Membrane blebbing during apoptosis results from caspase-mediated activation of ROCK I. Nat Cell Biol. 2001; 3(4):339-45. DOI: 10.1038/35070009. View

17.

Zhou Q, Liao J . Statins and cardiovascular diseases: from cholesterol lowering to pleiotropy. Curr Pharm Des. 2009; 15(5):467-78. PMC: 2896785. DOI: 10.2174/138161209787315684. View

18.

Pyne-Geithman G, Nair S, Caudell D, Clark J . PKC and Rho in vascular smooth muscle: activation by BOXes and SAH CSF. Front Biosci. 2007; 13:1526-34. PMC: 2430991. DOI: 10.2741/2778. View

19.

Leung T, Chen X, Manser E, Lim L . The p160 RhoA-binding kinase ROK alpha is a member of a kinase family and is involved in the reorganization of the cytoskeleton. Mol Cell Biol. 1996; 16(10):5313-27. PMC: 231530. DOI: 10.1128/MCB.16.10.5313. View

20.

Shimokawa H, Rashid M . Development of Rho-kinase inhibitors for cardiovascular medicine. Trends Pharmacol Sci. 2007; 28(6):296-302. DOI: 10.1016/j.tips.2007.04.006. View